Clinical Trials Logo

Clinical Trial Details — Status: Active, not recruiting

Administrative data

NCT number NCT03788291
Other study ID # ULYM18086
Secondary ID
Status Active, not recruiting
Phase Phase 2
First received
Last updated
Start date March 25, 2019
Est. completion date February 1, 2025

Study information

Verified date March 2024
Source University of Rochester
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The main purpose of this research study is to find out if the combination of acalabrutinib and high frequency low dose subcutaneous rituximab is safe and effective in patients who have previously untreated chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL).


Description:

Despite an array of available therapies, CLL remains an incurable disease. Furthermore, the presence of certain cytogenetic abnormalities and high-risk mutational features predicts for a reduced response to treatment, and as a result, a shorter period of progression-free survival. The development of a well-tolerated more effective, easily administered and limited duration therapy would be a major contribution to the management of CLL and other B cell malignancies. Acalabrutinib is an imidazopyrazine analogue and a potent inhibitor of BTK in vitro and in vivo. Acalabrutinib shows improved selectivity for BTK compared with ibrutinib. Functional inhibition of non-target cells (eg, T cells, NK cells, platelets) was not observed for acalabrutinib at clinically relevant concentrations. Rituximab is a chimeric monoclonal antibody targeting CD20 FDA approved for the treatment of CLL/SLL using intravenous or subcutaneous formulations. Antibody dependent cellular phagocytosis may be optimized using high frequency subcutaneous administration of anti-CD20 monoclonal antibodies. Unlike ibrutinib, acalabrutinib does not cause significant in vitro inhibition of rituximab induced antibody dependent cellular phagocytosis in vitro. The investigator thus proposes that acalabrutinib would be an ideal partner drug with high frequency low dose SQ rituximab in the treatment of CLL and that the combination will increase the efficacy of therapy for CLL patients by decreasing the time to achievement of complete response and allowing for shorter and less toxic therapy.


Recruitment information / eligibility

Status Active, not recruiting
Enrollment 39
Est. completion date February 1, 2025
Est. primary completion date May 19, 2023
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: 1. Diagnosis of B-cell CLL or SLL, with diagnosis established according to IWCLL criteria and documented within medical records. Patients must not have received previous therapy for CLL/SLL 2. CLL/SLL that warrants treatment consistent with accepted IWCLL criteria for initiation of therapy. Any one of the following conditions constitutes CLL/SLL that warrants treatment: 1. Evidence of progressive marrow failure as manifested by the onset or worsening of anemia and/or thrombocytopenia, or 2. Massive (i.e., lower edge of spleen =6 cm below the left costal margin), progressive, or symptomatic splenomegaly, or 3. Massive (i.e., =10 cm in the longest diameter), progressive, or symptomatic lymphadenopathy, or 4. Progressive lymphocytosis in the absence of infection, with an increase in blood absolute lymphocyte count (ALC) =50% over a 2-month period or lymphocyte doubling time of <6 months (as long as initial ALC was =30,000/L), or 5. Autoimmune anemia and/or thrombocytopenia that is poorly responsive to corticosteroids or other standard therapy, or 6. Constitutional symptoms, defined as any one or more of the following disease-related symptoms or signs occurring in the absence of evidence of infection: i. Unintentional weight loss of =10% within the previous 6 months, or ii. Significant fatigue (=Grade 2), or iii. Fevers >100.5°F or 38.0°C for =2 weeks, or iv. Drenching night sweats for >1 month. 3. Adequate organ system function, defined as follows: 1. Absolute neutrophil count (ANC) = 0.5x109/L and platelet count = 30x109/L 2. Total bilirubin =2.5 times the upper limit of normal (ULN) unless due to Gilbert's disease 3. Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =2.5 x ULN if no liver involvement or =5 x the ULN if known liver involvement 4. Calculated creatinine clearance >30 mL/min (as calculated by the Cockcroft-Gault formula) 5. Patients with PT/INR or aPTT =2xULN. 4. ECOG performance status = 2 unless related to CLL. 5. Male or female = 18 years of age. 6. Ability to swallow and retain oral medication. 7. Woman of childbearing potential (WOCBP) who are sexually active must use highly effective methods of contraception during treatment and for 2 days after the last dose of acalabrutinib and for 12 months following last dose of rituximab. (see Appendix 3 for examples) 8. Willingness and ability to comply with study and follow-up procedures, and give written informed consent. Exclusion Criteria: 1. Patients receiving cancer therapy (i.e., chemotherapy, radiation therapy, immunotherapy, biologic therapy, hormonal therapy, surgery). a. Systemic corticosteroid therapy started prior to study entry is allowed as clinically warranted. Topical or inhaled corticosteroids are permitted. 2. Serologic status reflecting active hepatitis B or C infection. Patients who are hepatitis B core antibody (anti-HBc) positive and who are surface antigen negative will need to have a negative polymerase chain reaction (PCR). Those who are hepatitis B surface antigen (HbsAg) positive or hepatitis B PCR positive will be excluded. Subjects who are hepatitis C antibody positive will need to have a negative PCR result. Those who are hepatitis C PCR positive will be excluded. 3. Known history of HIV. 4. Known histological transformation from CLL to an aggressive lymphoma. 5. Evidence of ongoing systemic bacterial, fungal or viral infection, except localized fungal infections of skin or nails. NOTE: Patients may be receiving prophylactic antiviral or antibacterial therapies at investigator discretion. 6. Live virus vaccines within 4 weeks prior to C1D1 or during rituximab therapy. 7. History of anaphylaxis (excluding infusion related reactions) in association with previous anti-CD20 administration or acalabrutinib. 8. Any severe and/or uncontrolled medical conditions or other conditions that could affect their participation in the study such as: 1. Symptomatic, or history of documented congestive heart failure (NY Heart Association functional classification III-IV) 2. Uncontrolled cardiac arrhythmia (Patients with controlled atrial fibrillation/flutter are eligible) 3. Myocardial infarction within 3 months of enrollment 4. Angina not well-controlled by medication 5. Poorly controlled or clinically significant atherosclerotic vascular disease including cerebrovascular accident (CVA), transient ischemic attack (TIA), angioplasty, cardiac/vascular stenting within 3 months of enrollment. 6. Active bleeding or history of bleeding diathesis (eg, hemophilia or von Willebrand disease). 7. Any history of intracranial bleed or stroke within 6 months of first dose of study drug 8. Patients with suspected or confirmed PML 9. Patients with malabsorption syndrome or gastrointestinal disease that limits absorption of oral medication 9. Malignancy within 2 years of study enrollment except for adequately treated basal, squamous cell carcinoma or non-melanomatous skin cancer, carcinoma in situ of the cervix, superficial bladder cancer not treated with intravesical chemotherapy or BCG within 6 months, localized prostate cancer and PSA <1.0 mg/dL on 2 consecutive measurements at least 3 months apart with the most recent one being within 4 weeks of study entry. 10. Patients with active uncontrolled autoimmune hemolytic anemia or ITP. 11. Inability to discontinue use of strong CYP3A inhibitors. Patients taking moderate CYP3A inhibitors or strong CYP3A inducers are eligible. 12. Requires or receiving anticoagulation with warfarin or equivalent vitamin K antagonists (eg, phenprocoumon) within 7 days of first dose of study drug. 13. Requires treatment with proton pump inhibitors (eg, omeprazole, esomeprazole, lansoprazole, dexlansoprazole, rabeprazole, or pantoprazole) at study entry. Subjects receiving proton pump inhibitors who switch to H2-receptor antagonists or antacids are eligible for enrollment to this study.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Acalabrutinib
100 mg by mouth twice a day starting on day 8 of cycle 1
Rituximab
Administered 2 times weekly for 6 cycles. Initial dose day 1: 50 mg IV, then 50 mg SQ thereafter.

Locations

Country Name City State
United States University of Rochester Rochester New York

Sponsors (1)

Lead Sponsor Collaborator
University of Rochester

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Proportion of subjects with a complete response rate (CR) at 1 year of therapy To satisfy criteria for a CR, all of the following criteria must be met:
No evidence of new disease
ALC in peripheral blood of <4 x 109/L
Regression of all target nodal masses to normal size =1.5 cm in the LD
Normal spleen and liver size
Regression to normal of all nodal non-target disease and disappearance of all detectable non-nodal, non-target disease
Morphologically negative bone marrow defined as <30% of nucleated cells being lymphoid cells and no lymphoid nodules in a bone marrow sample (the presence of benign reactive nodules is still compatible with a CR)
Absence of constitutional symptoms
Peripheral blood counts meeting all of the following criteria:
ANC >1.5 x 109/L without need for exogenous growth factors (e.g., G-CSF)
Platelet count =100 x 109/L without need for exogenous growth factors
Hemoglobin =110 g/L (11.0 g/dL) without red blood cell transfusions or need for exogenous growth factors (e.g., erythropoietin)
1 year
Secondary Proportion of subjects with minimal residual disease in peripheral blood and bone 6-color flow cytometry 1 year
See also
  Status Clinical Trial Phase
Recruiting NCT03588598 - Safety, Tolerability, and Pharmacokinetics of SHC014748M in Patients With Indolent B-Cell Hematologic Malignancies Phase 1
Recruiting NCT06043011 - Registry Platform Hematologic Malignancies (RUBIN) - Extension of Tumor Registry Lymphatic Neoplasms
Completed NCT02265731 - Study Evaluating Venetoclax in Subjects With Hematological Malignancies Phase 1/Phase 2
Completed NCT02582879 - informCLL™: A Disease Registry for Patients With Chronic Lymphocytic Leukemia
Completed NCT02553304 - Molecular Features Underlying Racial Differences in Survival of Taiwanese Chronic Lymphocytic Leukemia Patients
Completed NCT01419691 - Phase I and II Study of Auranofin in Chronic Lymphocytic Leukemia (CLL) Phase 2
Completed NCT01188681 - Safety and Efficacy Study of TRU-016 Plus Bendamustine vs. Bendamustine in Relapsed Chronic Lymphocytic Leukemia Phase 1/Phase 2
Recruiting NCT04758975 - Venetoclax, Rituximab and Ibrutinib in TN Patients With CLL Undetectable Minimal Residual Disease (uMRD) in Treatment-naïve Patients With Chronic Lymphocytic Leukemia (CLL) Phase 2
Terminated NCT02914938 - A Study of ME-401 in Subjects With CLL/SLL, FL, and B-cell Non Hodgkin's Lymphoma Phase 1
Active, not recruiting NCT01976520 - Vaccine Therapy for Treating Patients With Previously Untreated Chronic Lymphocytic Leukemia (CLL) Phase 1
Terminated NCT01463852 - A Study of the Effect of Vinca Alkaloids on c-Jun N-terminal Kinase (JNK) Phosphorylation in Patients With Chronic Lymphocytic Leukemia (CLL) Phase 0
Terminated NCT01203930 - A Study of Idelalisib and Rituximab in Elderly Patients With Untreated CLL or SLL Phase 2
Recruiting NCT02966756 - A Study of Venetoclax in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Phase 2
Active, not recruiting NCT05105841 - Study to Assess Change in Disease Activity and Adverse Events of Oral Venetoclax in Combination With Intravenous (IV) Obinutuzumab or Oral Ibrutinib in Adult Participants With Untreated Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) Phase 2
Recruiting NCT04072458 - A Clinical Trial of BP1002 in Patients With Advanced Lymphoid Malignancies Phase 1
Withdrawn NCT01754870 - Phase II Study of Bendamustine and Rituximab Induction Chemoimmunotherapy Followed by Maintenance Rituximab (Rituxan®) and Lenalidomide (Revlimid®) in Relapsed and Refractory Chronic Lymphocytic Leukemia (CLL) and Small Lymphocytic Lymphoma (SLL) Phase 2
Recruiting NCT01758042 - Bone Marrow and Kidney Transplant for Patients With Chronic Kidney Disease and Blood Disorders N/A
Completed NCT01885897 - IL-15 Super Agonist ALT-803 to Treat Relapse Of Hematologic Malignancy After Allogeneic SCT Phase 1/Phase 2
Active, not recruiting NCT04830137 - A Study of NX-2127 in Adults With Relapsed/Refractory B-cell Malignancies Phase 1
Recruiting NCT03547115 - A Study of Voruciclib Alone or in Combination With Venetoclax in Subjects With B-Cell Malignancies or AML Phase 1